This collaboration can allow better reach of biomarker-directed ADC directly to patients.

Japan: On Tuesday, August 29, 2023, ImmunoGen recently unveiled an exclusive collaboration with Takeda Pharmaceutical Company. The partnership centers around the development and commercialization of Elahere (mirvetuximab soravtansine-gynx) in Japan.

Under the terms of this agreement, ImmunoGen is poised to receive an upfront payment, complemented by an additional sum upon the conversion of Elahere's accelerated approval from the US Food and Drug Administration (FDA) for treating platinum-resistant ovarian cancer (PROC) into a full approval status. This accord also stipulates potential supplementary payments to ImmunoGen, contingent on Takeda's attainment of specific regulatory and commercial milestones. Takeda, in return, will secure an exclusive license for the development and commercialization of Elahere within the Japanese market, taking on the responsibilities associated with regulatory submissions and obligations.

ImmunoGen's President and CEO, Mark Enyedy, conveyed his confidence in the partnership, stating, "Given Takeda's extensive track record as an oncology product development and commercialization leader spanning over two decades, along with their profound roots and influence in Japan, they are the perfect collaborator to facilitate the delivery of Elahere to eligible patients in this crucial market." Enyedy also emphasized the collaboration's significance, noting its alignment with ImmunoGen's commitment to making Elahere, a biomarker-directed ADC with transformative potential, accessible to patients on a global scale.

Teresa Bitetti, President of Takeda's Global Oncology Business Unit, echoed the sentiment of the partnership's significance, noting, "The introduction of Elahere to the Japanese market addresses the considerable treatment gap for ovarian cancer patients, particularly those grappling with resistance to platinum-based therapies. The insights derived from the phase 3 MIRASOL study underscore Elahere's potential to establish a new treatment standard for this devastating disease. With our collaboration with ImmunoGen, we are confident in delivering substantial value to patients in Japan." Bitetti also underscored Takeda's commitment to collaborating with organizations that share their dedication to developing novel treatments for cancers that suffer from inadequate or ineffective therapeutic options, aligning with their overarching aspiration to combat cancer comprehensively.

This partnership stands as a testament to the shared determination of Takeda and ImmunoGen, working harmoniously to advance medical solutions for cancer patients, ultimately driving towards the goal of eradicating cancer.